Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz...
10
Simon K. Cheng 1 , Kevin Stephenson 2 , Lynn Shi 2 , Kunal Chaudhary 1 , Anshu Jain 1 , David P. Horowitz 1 , Sherry X. Yan 2 , Tony Wang 1 , Clifford Chao 1 , Tom K. Hei 1 1 New York Presbyterian Hospital / Columbia University Medical Center, 2 Columbia University, New York, NY oster # 1139
-
Upload
evangeline-hill -
Category
Documents
-
view
218 -
download
1
Transcript of Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz...
Simon K. Cheng1, Kevin Stephenson2, Lynn Shi2, Kunal Chaudhary1, Anshu Jain1, David P. Horowitz1, Sherry X. Yan2, Tony Wang1,
Clifford Chao1, Tom K. Hei1
1New York Presbyterian Hospital / Columbia University Medical Center, 2Columbia University, New York, NY
Poster # 1139
Disclosures: None
– cancer patients are exposed to catecholamines under chronic stress conditions
– promotes cellular proliferation, tumor invasion, angiogenesis, and resistance to chemotherapy-induced apoptosis
– beta-blockers commonly used to treat hypertension and cardiac disease
PC9 lung cancer cells
No BB BBTotal patients
(n=101)80% 20%
Age (avg) 64 yo 68 yo
Males 60% 71%
Stage IIIA N2+
75%73%
78%66%
HistologySquamous
AdenoCarcinoma NOS
26%57%16%
36%52%10%
NSNS
p=0.007
*
No BB BB
OS 1yr
68%82% (SS)
OS 2yr
53% 72% (NS)
– β-adrenergic pathway may regulate multiple processes that contribute to tumor progression and treatment response
– propranolol radiosensitizes lung cancer cells to radiation in vitro
– beta-blocker use was associated with a decreased distant metastases rate and improved overall survival at 1 year In LA-NSCLC pts treated with tri-modality therapy
– Need additional studies evaluating the benefits of beta-blocker use on radiation treatment response and lung cancer recurrence
– Commonly targeted medical pathways may have significant pleomorphic effects on the efficacy of cancer therapies
– e.g. NRG LU001
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
